News Releases

News & Events

News Releases

Synteract Appoints Vice President of Global Clinical Operations

CRO veteran Dr. Dieter Seitz-Tutter joins leading organization serving emerging and mid-sized biopharma companies

SAN DIEGO – Oct. 27, 2015 – Synteract has hired Dr. Dieter Seitz-Tutter as vice president, global clinical operations. This new position was established to accommodate the continued growth of the company as Synteract extends its reach supporting the drug development programs of small to mid-sized biopharma companies.

Sietz-Tutter will join the senior management team, helping to proactively ensure proper planning, conduct, patient safety, data quality, and all processes critical to clinical development. He will lead the company’s experienced clinical operations teams while fostering good communication between Synteract, study sites and the sponsor.

“Dieter’s extensive experience in the CRO industry and his knowledge of the global clinical market are very valuable to our clients. He knows the emphasis we place on studies being completed successfully—on time, within budget, and in compliance with regulatory requirements,” said Wendel Barr, CEO. “We are pleased to add his industry and clinical expertise to our seasoned leadership team.”

Seitz-Tutter has more than 25 years of experience in clinical research—20 of which he spent in the CRO industry. Most recently, Seitz-Tutter was vice president of global clinical development at Chiltern where he was responsible for all clinical and country operations outside of North America. He also served as vice president for Europe at Medpace where he was responsible for clinical operations in 17 countries across Europe and Israel. Earlier in his career, he spent 13 years at Kendle where he served in different roles, including director of business development Europe, managing director Germany and vice president global clinical development Europe.

Dr. Seitz-Tutter holds a Master of Science and Doctor of Science degree in biology from Ludwig Maximilian University of Munich. He will work from the Synteract Munich office.

About Synteract
Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, Synteract provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.

# # #

Amanda Whitlock


Contact Synteract

Tell us how to stay in touch with you: